Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2018



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Lymphocytes and their Roles in Cancer (R1)


Organizer(s) Iannis Aifantis, Ugur Sahin and Mikala Egeblad
February 11—15, 2018
Keystone Resort • Keystone, Colorado USA
Discounted Abstract Deadline: Oct 11, 2017
Abstract Deadline: Dec 13, 2017
Scholarship Deadline: Oct 11, 2017
Discounted Registration Deadline: Dec 13, 2017

Sponsored by Amgen Inc., BioLegend, Inc. and Incyte Corporation


Summary of Meeting:
Leverage of the body’s own immune system is revolutionizing the way that we treat cancer as it can lead to dramatic and durable responses. Such anti-tumor therapies include reactivation of anti-tumor T cells, expansion of tumor-infiltrating lymphocytes (TILs), Chimeric antigen receptor (CAR) T cells and a variety of cancer vaccines. The focus or target of most these approaches are cells of the lymphocytic lineage (T, B, NK, dendritic cells), key components of both adaptive and innate immune response. At the same time, lymphocytes can also be malignant, as in the case of a large number of lymphocytic leukemia and lymphoma subtypes, and active components of the immune microenvironment, controlling tumor growth and anti-tumor response. This conference for the first time brings together scientists from these different areas of lymphocyte biology and provides an overview of lymphocyte development, transformation, terminal differentiation, location within the tumor microenvironment and anti-tumor activity. The conference also provides an update on novel therapy protocols that attempt to harness the function of lymphocytes against cancer and state-of-the-art technologies, including imaging and DNA/RNA sequencing approaches, that will help us visualize and molecularly dissect anti-tumor responses in experimental systems and cancer patients.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, February 11 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 15 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 16 in order to fully experience the meeting.

SUNDAY, FEBRUARY 11

16:00—20:00
Arrival and Registration

Longs Peak Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Longs Peak Foyer

MONDAY, FEBRUARY 12

07:00—08:00
Breakfast

Colorado Rockies Ballroom
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Quandary Peak
* Iannis Aifantis, New York University School of Medicine, USA

Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Regulatory T Cells and their Functions in the Tumor Microenvironment

08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
* Carl H. June, University of Pennsylvania, USA

* Bruce R. Blazar, University of Minnesota, USA

* Marcela V. Maus, Harvard Medical School, USA

Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
T Cell Recognition in Human Cancer

09:00—11:15
Understanding Lymphocytic Malignancy: Leukemia and Lymphoma
Meeting has ended...abstracts no longer viewable online.

Quandary Peak
* Adolfo Ferrando, Columbia University, USA

Louis M. Staudt, NCI, National Institutes of Health, USA
The MYD88-TLR9-B Cell Receptor Complex as a Target for Therapy in Aggressive Lymphomas

Coffee Break

Charles G. Mullighan, St. Jude Children's Research Hospital, USA
The Role of CREBBP Mutations in Drug Resistance in Acute Lymphoblastic Leukemia

Katia Georgopoulos, Massachusetts General Hospital, USA
Super-Enhancer Circuits in B Cell Development and Transformation

Anastasia N. Tikhonova, New York University Medical School, USA
Short Talk: Single-Cell Dynamics of Bone Marrow Microenvironment

09:00—11:30
CAR/TCR Preclinical
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
* Carl H. June, University of Pennsylvania, USA

Philip D. Greenberg, University of Washington, USA
Making TCR-Modified T Cells Effective for Leukemia and Solid Tumors

Coffee Break

Crystal L. Mackall, Stanford University, USA
What’s Next? Preclinical Studies Paving the Way for Future CAR T Cell Trials

Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
Strategies to Improve the Efficacy of CAR T Cells in Solid Tumors

Reno Debets, Erasmus MC Cancer Institute, Netherlands
Short Talk: T Cell Receptors Equipped with ICOS Enhance T Cell Persistence and Mediate Sustainable Anti-Tumor Responses upon Adoptive T Cell Therapy

James Scott-Browne, La Jolla Institute, USA
Short Talk: Transcriptional Control of CAR-T Cell Function in Solid Tumors

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Colorado Rockies Ballroom
13:00—22:00
Poster Viewing

Colorado Rockies Ballroom
14:30—16:30
Workshop 1: Understanding and Targeting Lymphocytes in Cancer

Quandary Peak
* Iannis Aifantis, New York University School of Medicine, USA

Eirini Giannakopoulou, Radiumhospitalet, Norway
T Cell Receptor-Mediated Targeting of Recurrent Neoantigens in Acute Myeloid Leukemia

Wenting Zheng, St. Jude Children Research Hospital, USA
PI3K Orchestration of the in vivo Persistence of Chimeric Antigen Receptor-Modified T Cells

Elena Montauti, Northwestern University, USA
USP22 Maintains Regulatory T Cells by Stabilizing Foxp3 Protein Level and Impairs Anti-Tumor Immune Response

Jeffrey Ward, Washington University School of Medicine, USA
Remodeling of Myeloid as well as Lymphoid Compartments following Checkpoint Blockade Immunotherapy

Soki Kashima, Kyoto University, Japan
WT1-Specific Cytotoxic T Lymphocytes Regenerated from T Cell-Derived iPS Cells Exert Therapeutic Effect in Xenograft Model of Renal Cell Carcinoma

Chris Nicolai, University of California, Berkeley, USA
Mechanisms of MHC-Deficient Tumor Clearance using STING Agonists

Julie A. Rytlewski, Adaptive Biotechnologies, USA
History of Prior Immunotherapy Changes Relationship between Tumor Mutations and TIL Repertoire

Angela Vasaturo, INSERM, UMRS 1138, France
Unraveling the Immune Contexture of Pre-Invasive Lesions of the Lung by Multispectral Imaging

14:30—16:30
Workshop 1: Perspectives from Industry

Grays/Longs Peak
* Charles Sentman, Geisel School of Medicine at Dartmouth, USA

Amy Gilbert, Cell Design Labs, USA
Development of a SynNotch Combinatorial “and” Gate CAR T for Solid Tumors

Ian R. Hardy, Fate Therapeutics, USA
Improving CAR-T Cell Function with Small Molecule Treatment during Production

Kelan Hlavaty, SQZ Biotech, USA
Engineering T Cells Using a Microfluidic Intracellular Delivery Method for Cell Therapy

Robert Hofmeister, TCR2 Therapeutics, USA
A Novel T Cell Therapy Engaging the Complete T Cell Receptor

Lenka Hurton, MD Anderson Cancer Center, USA
Rapid Production of T Cells Co-expressing CAR and Membrane-bound IL-15 Potentiates Antitumor Activity and Promotes in vivo Memory

Sumiti Jain, Sangamo Therapeutics, USA
Precise T Cell Engineering using Enhanced Zinc-finger Nucleases (ZFNs) for Highly Specific and Efficient Dual Knock-Out of Endogenous T-Cell Receptor and HLA-Class I with Site-Specific Insertion of a CD19-CAR: Implications for Allogeneic T Cell Therapy

Inez Johanna, University Medical Center Utrecht, Netherlands
Towards the Next Generation CAR T Cells with TEGs: In vivo Efficacy – Toxicity Profile in Xenografts of Primary Human AML Disease and Healthy Bone Marrow

Levi Rupp, Cell Design Labs, USA
THROTTLETM CARs: A Novel Platform for Enhanced Safety and Efficacy via Titratable Control of CAR-T Activity using an FDA-Approved Small Molecule

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Therapeutic Targeting of Lymphocytic Malignancy
Meeting has ended...abstracts no longer viewable online.

Quandary Peak
* Charles G. Mullighan, St. Jude Children's Research Hospital, USA

Adolfo Ferrando, Columbia University, USA
Epigenetic Mechanisms in T-Cell Acute Lymphoblastic Leukemia

Iannis Aifantis, New York University School of Medicine, USA
Targeting Stress Responses in Acute Lymphocytic Leukemia

Andrei Thomas-Tikhonenko, Children's Hospital of Philadelphia and University of Pennsylvania, USA
Escape Hatches for Immunotherapies Targeting B-Cell Differentiation Antigens

Jacques G. M. Ghysdael, Institut Curie, France
Short Talk: Triggering the Tcr Developmental Checkpoint Activates a Therapeutically Targetable Anti-Leukemic Pathway in T-Cell Acute Lymphoblastic Leukemia

17:00—19:00
Synthetic Biology
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
* Crystal L. Mackall, Stanford University, USA

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Chemically Engineering T Cell Therapies

Wendell A. Lim, University of California, San Francisco, USA
Optimizing Synthetic Biology Tools for T Cell Therapies

Travis Young, California Institute for Biomedical Research, USA
Controllable CAR-T Cell Therapy

Patrick Ho, University of California, Los Angeles, USA
Short Talk: COVERT T Cells: Engineering T Cells to Interrogate Intracellular Antigens

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
19:30—22:00
Poster Session 1

Colorado Rockies Ballroom

TUESDAY, FEBRUARY 13

07:00—08:00
Breakfast

Colorado Rockies Ballroom
08:00—11:00
Cellular Therapies in Blood Malignancies and Beyond
Meeting has ended...abstracts no longer viewable online.

Quandary Peak
* Ugur Sahin, TRON – Translationale Oncology, Germany

Carl H. June, University of Pennsylvania, USA
CAR T Cells and their Therapeutic Promise in the Treatment of Leukemia

Crystal L. Mackall, Stanford University, USA
CAR Vulnerabilities: Emerging Insights from Clinical Trials

Coffee Break

Chiara Bonini, Vita Salute San Raffaele University, Italy
Gene Editing of Memory Stem T Cells for Cancer Immunotherapy

Justin Eyquem, Memorial Sloan Kettering Cancer Center, USA
Precision T Cell Engineering to Advance Adoptive T Cell Therapies

Charlotte Mousset, Radboudumc, Netherlands
Short Talk: Superior Multi-Functionality and Glycolytic Function of Tumor-Reactive CD8+ TSCM-Like T Cells by ex vivo Akt-Inhibition

08:00—11:00
Engineered T Cells for Viruses
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
* Philip D. Greenberg, University of Washington, USA

Catherine M. Bollard, Children’s National Health System, USA
Developing HIV-Specific T Cell Therapies: Lessons from EBV

Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Shutting the Door on HIV by Engineering Hematopoietic Stem Cells

Coffee Break

James L. Riley, University of Pennsylvania, USA
Engineering T Cells to Functionally Cure HIV-1 Infection

Scott G. Kitchen, University of California, Los Angeles AIDS Institute, USA
Engineering Antiviral CAR T Cell Immunity through Hematopoietic Stem/Progenitor Cells

Alok Vishnu Joglekar, California Institute of Technology, USA
Short Talk: Hematopoietic Stem/Progenitor Cells Engineered with T Cell Receptors for Immunotherapy for HIV Infection

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Colorado Rockies Ballroom
13:00—22:00
Poster Viewing

Colorado Rockies Ballroom
16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Lymphocytes as Elements of the Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online.

Quandary Peak
* Katia Georgopoulos, Massachusetts General Hospital, USA

David H. Raulet, University of California, Berkeley, USA
Natural Killer Cell Activation and Inhibition: Potential for Cancer Therapy

Michael Khodadoust, Stanford University, USA
T Cell Recognition of Lymphoma Immunoglobulin

Mikala Egeblad, Cold Spring Harbor Laboratory, USA
Visualization of the Switch from Immune Control to Immune Escape

Annelise Snyder, University of Washington, USA
Short Talk: Anti-tumor Effects of Inflammatory Necroptosis Within the Tumor Microenvironment

17:00—19:00
CAR/TCR in the Clinic for Cancer
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
* Jeffrey Steven Miller, University of Minnesota, USA

Stephen J. Forman, City of Hope, USA
CAR T Cells for Treatment of Central Nervous System (CNS) Malignancy

Marcela V. Maus, Harvard Medical School, USA
CAR T Cells Multiple Myeloma and Glioblastoma

Saar I. Gill, University of Pennsylvania, USA
CAR T Cells for Acute Myelogenous Leukemia

Jenessa Barbara Smith, Poseida Therapeutics, USA
Short Talk: PSMA-Specific CAR T-Stem Cell Memory Therapy Eliminates Solid Tumor in Prostate Cancer Model

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
19:30—22:00
Poster Session 2

Colorado Rockies Ballroom

WEDNESDAY, FEBRUARY 14

07:00—08:00
Breakfast

Colorado Rockies Ballroom
08:00—11:00
Emerging Technologies: Visualization and Dissection of the Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online.

Quandary Peak
* Mikala Egeblad, Cold Spring Harbor Laboratory, USA

Dana Pe'er, Memorial Sloan Kettering Cancer Center, USA
A Single Cell Approach to Understanding the Tumor Microenvironment

Matthew F. Krummel, University of California, San Francisco, USA
Imaging a World beyond Checkpoints: Innate Partners for Lymphocytes in Cancer

Coffee Break

Jerome Galon, INSERM U872, Cordeliers Research Center, France
Immunoscore as a Stronger Predictor of Patient Survival in Colorectal Cancer

Michael Goldberg, Dana-Farber Cancer Institute, USA
Enhancing Cancer Immunotherapy through Immuno-engineering

08:00—11:15
Tregs as Cellular Therapeutics
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
* James L. Riley, University of Pennsylvania, USA

Bruce R. Blazar, University of Minnesota, USA
Vimentin Restrains Regulatory T-cell Suppression of Graft-versus-Host Disease

Jeffrey A. Bluestone, University of California, San Francisco, USA
Manipulating Tregs to Control Tolerance in Autoimmunity and Cancer

Coffee Break

Megan K. Levings, University of British Columbia, Canada
HLA-A2 Directed CAR Tregs

David Klatzmann, Sorbonne University Medical School, France
IL-2 for Treg-Based Immunotherapies: In (and Out)

Angela C. Boroughs, Massachusetts General Hospital/Harvard University, USA
Short Talk: 4-1BB Co-Stimulation Inhibits CAR Treg Suppressive Function

Elmar Jaeckel, Hannover Medical School, Germany
Short Talk: Operational Tolerance in Allotransplantation by Use of Regulatory T Cells with a MHC-Specific Chimeric Antigen Receptor

11:15—17:00
On Own for Lunch

14:30—16:30
Workshop 2: Cell Engineering

Grays/Longs Peak
* Martin Pule, University College London, UK

Zinaida Good, Stanford University, USA
Guiding T-Lymphocyte Differentiation in Cancer Immunotherapy Applications

Rachel C. Lynn, Stanford University, USA
Disrupting the Balance: Engineering AP1 to Overcome CAR T Cell Exhaustion

Shannon K. Oda, Fred Hutchinson Cancer Research Center, USA
Cheating Death: A Fas-4-1BB Immunomodulatory Fusion Protein Obviates a Death Signal to Enhance T Cell Function and Adoptive Therapy Targeting Leukemia and Solid Tumors

William Lemieux, University of Montréal, Canada
Efficient Transduction of Nk Cells Method Resulting in a Robust and Sustained Transgene Expression for Immunotherapy

Masataka Suzuki, Baylor College of Medicine, USA
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments Chimeric Antigen Receptor T-Cell against Metastatic Head and Neck Cancer

Tori Yamamoto, NCI, University of Pennsylvania, USA
Cell Intrinsic Fas Signaling Inhibition to Improve Therapeutic Efficacy of T Cells

Nicholas F. Kuhn, Memorial Sloan Kettering Cancer Center, USA
Design of a Systemic Antitumor Response with CD40L-modified CAR T Cells

Joy (Yushu) Xie, Massachusetts Institute of Technology, USA
Engineering Single Domain Antibody-Based Chimeric Antigen Receptor T Cells for Treatment of Solid Tumors

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Emerging Concepts in the Development of Tumor Vaccines
Meeting has ended...abstracts no longer viewable online.

Quandary Peak
* Dimitris Skokos, Regeneron Pharmaceuticals, USA

Ugur Sahin, TRON – Translationale Oncology, Germany
Systemic RNA Delivery, Dendritic Cell Vaccines and Implications for Cancer Immunotherapy

Cornelis J. M. Melief, Leiden University Medical Center, Netherlands
Combination Immunotherapy of Cancers Caused by High-Risk HPV16

Johanna Olweus, University of Oslo, Norway
Selecting Immunogenic Targets for Cancer Immunotherapy

Samarth Hegde, Washington University School of Medicine, USA
Short Talk: Tumor Antigenicity Accelerates Early Pancreatic Adenocarcinoma Progression

17:00—19:00
Beyond T Cells: HSC, T Progenitor and IPSCs I
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
* Juan Carlos Zúñiga-Pflücker, Sunnybrook Research Institute, Canada

Martin Pule, University College London, UK
New Designs in Synthetic T Cells

Jeffrey Steven Miller, University of Minnesota, USA
Novel Ways to Activate and Target NK Cells to Treat Cancer

Linda T. Vo, University of California, San Francisco, USA
T Cell Engineering from Human Pluripotent Stem Cells

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom

THURSDAY, FEBRUARY 15

07:00—08:00
Breakfast

Colorado Rockies Ballroom
08:00—11:00
Combinatorial Treatments and their Effects on Lymphocyte Function in Cancer
Meeting has ended...abstracts no longer viewable online.

Quandary Peak
* Ashley M. Laughney, Memorial Sloan Kettering Cancer Center, USA

David G. DeNardo, Washington University Medical School, USA
The Pancreatic Tumor Microenvironment; Modulator of Tumor Progression and Response to Therapy

Dimitris Skokos, Regeneron Pharmaceuticals, USA
T Cell Dysfunction and Combination Immunotherapy

Coffee Break

Michael A. Curran, University of Texas MD Anderson Cancer Center, USA
Optimizing T Cell Frequency and Function via Checkpoint Antibody / Vaccine Combinations

Sjoerd H. van der Burg, Leiden University Medical Center, Netherlands
Combination Treatments to Modulate the Microenvironment and Boost Tumor-Specific T Cells

Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, USA
Short Talk: IL-35+ B Cells Establish Immunosuppressive Network in Pancreatic Ductal Adenocarcinoma

08:00—11:00
Beyond T Cells: HSC, T Progenitor and IPSCs II
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
* Bruce R. Blazar, University of Minnesota, USA

Juan Carlos Zúñiga-Pflücker, Sunnybrook Research Institute, Canada
Generation of Human Progenitor T Cells from Stem Cells

Sjoukje J.C. van der Stegen, Memorial Sloan Kettering Cancer Center, USA
Development of CD8alphabeta+ CAR T Cells from Human Pluripotent Stem Cells

Coffee Break

Jakub Tolar, University of Minnesota, USA
Gene-Edited Stem Cells: From Cloning to Clinic

Saar I. Gill, University of Pennsylvania, USA
Chimeric Antigen Receptor Macrophages for the Treatment of Solid Tumors

Katelyn Masiuk, University of California, Los Angeles, USA
Short Talk: Hematopoietic Stem Cell Gene Therapy for IPEX Syndrome

11:00—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—18:45
Future Directions for Next-Generation Sequencing: Genomics, Epigenetics and Immunogenomics
Meeting has ended...abstracts no longer viewable online.

Quandary Peak
* Iannis Aifantis, New York University School of Medicine, USA

Ashley M. Laughney, Memorial Sloan Kettering Cancer Center, USA
Dissecting Tumor Cell Plasticity and Population Interactions Supporting Metastasis using Single Cell Genomics

Mickey Atwal, Cold Spring Harbor Laboratory, USA
High-Throughput Profiling of T Cell Receptor Sequences in Cancer Immunotherapy

Rahul Satija, New York Genome Center, USA
Integrated Analysis of Single Cell Data across Modalities, Technologies and Species

17:00—18:45
Intersection of Genetic Editing and Cellular Therapy
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
* Marcela V. Maus, Harvard Medical School, USA

Alex Marson, University of California, San Francisco, USA
Reprogramming Human T Cell Circuitry

Andrew M. Scharenberg, Casebia Therapeutics, USA
Engineering Regulatory T Cells for Inflammatory Disorders

Carl H. June, University of Pennsylvania, USA
Adoptive Transfer with Genetically Edited T Cells

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Quandary Peak
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Grays/Longs Peak
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Colorado Rockies Ballroom

FRIDAY, FEBRUARY 16

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Amgen Inc. BioLegend, Inc.
Incyte Corporation
 

We gratefully acknowledge additional support for this conference from:

American Association for Cancer Research (AACR) Bethyl Laboratories, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676